Related Business Topics
Latest Headlines
Reuters - Nov. 18, 2009, 1:15 PM
RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, ...
CNBC - Nov. 18, 2009, 12:50 PM
Forbes.com - Oct. 28, 2009, 1:57 PM
RICHMOND, Calif. 'Sangamo scientists have developed a ZFN-mediated gene-editing technology that has been demonstrated to make hematopoietic stem cells and mature immune system cells resistant to HIV infection,' said Dr. Zaia. 'This will be the first ...
Forbes.com - Oct. 13, 2009, 11:06 AM
RICHMOND, Calif. Jefferies & Company, Inc. acted as sole book-running manager in this offering. A registration statement relating to the shares of common stock issued in the offering has been filed with, and declared effective by, the Securities and ...
0-9 |
A |
B |
C |
D |
E |
F |
G |
H |
I |
J |
K |
L |
M |
N |
O |
P |
Q |
R |
S |
T |
U |
V |
W |
X |
Y |
Z
S
Sangamo Biosciences
Sangamo BioSciences, Inc. is a privately held biotechnology company focused on the rational design of novel transcription factors for the recognition and regulation of mammalian, plant and microbial gene targets.
www.sangamo.com
Sangamo BioSciences, Inc. is a privately held biotechnology company focused on the rational design of novel transcription factors for the recognition and regulation of mammalian, plant and microbial gene targets.
www.sangamo.com
